Johnson & Johnson (JNJ) at $268.73 after a 15.4% three-month gain; P/E 40.88

What the company does

Johnson & Johnson is listed on the NYSE and is based in New Jersey, U.S.A. It operates in the pharmaceuticals industry within the health care sector. Its latest profitability figures show a gross margin of 67.6%, an operating margin of 25.2% and a net margin of 16.2%, with return on equity at 19.7%. Revenue grew 7.8% year over year, while debt to equity stands at 0.55.

Price action and valuation versus peers

Over about six months the shares are up 19.9%, and over three months up 15.4%, while the one-month move was down 0.3%. The six-month high was $278.43 on 2026-09-03 and the low was $221.32 on 2026-05-08, so the last price of $268.73 sits below the peak. The stock rose 0.91% on the day. Its P/E is 40.88, P/S 6.51, P/B 7.93 and EV/EBITDA 20.35. The tracked Health Care peer median P/E, based on UNH and LLY, is 42.89, slightly above Johnson & Johnson's 40.88. Earnings were down 35.9% year over year.

What the recent headlines say

Recent coverage centres on prostate cancer research. BioSpace reported on 2026-10-26 that J&J delivered ‘immaculate’ early data for a prostate cancer drug from Halda at ESMO 2026. Yahoo reported Phase 1 prostate cancer drug results from the same meeting, and Seeking Alpha cited a 75% tumor response rate for a novel prostate cancer therapy. CNBC described a potential ‘game-changer’ drug. TIKR.com covered UK approval of the company's psoriasis pill, and 24/7 Wall St. featured the stock among S&P 500 dividend ideas.

Fundamentals

Recent headlines

• J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean - CNBC CNBC · 2026-10-26
• ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda - BioSpace BioSpace · 2026-10-26
• Johnson & Johnson Reports Phase 1 Prostate Cancer Drug Results at ESMO 2026 - Yahoo Yahoo · 2026-10-26
• 2 Safe S&P 500 Dividend Stocks Boomers Can Buy and Hold Forever - 24/7 Wall St. 24/7 Wall St. · 2026-10-26
• J&J reports 75% tumor response rate with novel prostate cancer therapy - Seeking Alpha Seeking Alpha · 2026-10-26
• Johnson & Johnson Won UK Approval for Its Psoriasis Pill. Here’s Where the Stock Could Go by 2030 - TIKR.com TIKR.com · 2026-10-26

In the AgentFlare Newswire

• Big banks kick off earnings season on Tuesday ahead of CPI data 2026-10-11 · earnings
• Big banks kick off earnings season on Tuesday 2026-10-11 · macro

What to watch

• Phase 1 prostate cancer drug results presented at ESMO 2026
• Johnson & Johnson's psoriasis pill following its UK approval

FAQ

How this page is made. Prices, fundamentals and headlines come from the AISA Financial API; peers are the other tracked stocks in the same sector. The profile is written by a language model from those numbers and headlines only — figures not in the data are removed. Nothing here is investment advice.